| Autor: |
Muniesa, Cristina, Gallardo, Fernando, García‐Doval, Ignacio, Estrach, M. Teresa, Combalia, Andrea, Morillo‐Andújar, Mercedes, De la Cruz‐Vicente, Fátima, Machan, Salma, Moya‐Martínez, Cristina, Rovira, Roger, Sanchez‐Gonzalez, Blanca, Acebo, Elvira, Amutio, Elena, Peñate, Yeray, Losada‐Castillo, Maria del Carmen, García‐Muret, M. Pilar, Iznardo, Helena, Román‐Curto, Concepción, Cañueto, Javier, Fernández‐de‐Misa, Ricardo |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Jan2023, Vol. 37 Issue 1, p57-64, 8p |
| Abstrakt: |
ABSTRCT: Background: Brentuximab vedotin (BV) has been approved for CD30‐expressing cutaneous T‐cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL. Methods: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). Results: Sixty‐seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty‐eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow‐up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow‐up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. Conclusions: These results confirm the efficacy and safety of BV in patients with advanced‐stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text